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Abstract
The presence of lymph node (LN) metastases is one of the most important negative prognostic factors in upper gas-
trointestinal carcinomas. Tumour regression similar to that in primary tumours can be observed in LN metastases
after neoadjuvant therapy. We evaluated the prognostic impact of histological regression in LNs in 480 adenocarci-
nomas of the stomach and gastro-oesophageal junction after neoadjuvant chemotherapy. Regressive changes in LNs
(nodular and/or hyaline fibrosis, sheets of foamy histiocytes or acellular mucin) were assessed by histology. In total,
regressive changes were observed in 128 of 480 patients. LNs were categorised according to the absence or presence
of both residual tumour and regressive changes (LN−/+ and Reg−/+). 139 cases were LN−/Reg−, 28 cases without
viable LN metastases revealed regressive changes (LN−/Reg+), 100 of 313 cases with LN metastases showed regres-
sive changes (LN+/Reg+), and 213 of 313 metastatic LN had no signs of regression (LN+/Reg−). Overall, LN/Reg
categorisation correlated with overall survival with the best prognosis for LN−/Reg− and the worst prognosis for
LN+/Reg− (p < 0.001). LN−/Reg+ cases had a nearly significant better outcome than LN+/Reg+ (p = 0.054) and
the latter had a significantly better prognosis than LN+/Reg− (p = 0.01). The LN/Reg categorisation was also an
independent prognostic factor in multivariate analysis (HR = 1.23; 95% CI 1.1–1.38; p < 0.001). We conclude that
the presence of regressive changes after neoadjuvant treatment in LNs and LN metastases of gastric and gastro-
oesophageal junction cancers is a relevant prognostic factor.
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Introduction
The presence of lymph node (LN) metastases is one
of the most important negative prognostic factors
for oesophageal and gastric cancer patients after
surgical resection [1–4]. This is true both for
patients who are treated by primary resection and
for those who are treated with multimodal treatment
including neoadjuvant chemotherapy followed by
surgery [5–7]. Regression of the primary tumour is
associated with favourable outcome after
neoadjuvant therapy followed by surgery in gastric
cancer [8]. Histopathological assessment of tumour
regression of gastrointestinal carcinomas is usually
performed on the primary tumours and the most
commonly used grading systems solely include the
evaluation of regression at the site of the primary
tumour [9,10]. Regressive changes, however, can
also be observed in LN metastases [11–13] and the
currently reported sole information about the
absence or presence of LN metastases along with
the number of affected LNs by UICC/AJCC TNM
© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley &
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staging [14] may thus not mirror the specific clinical
situation if previous LN metastases have regressed
under preoperative chemotherapy. It is therefore not
clear if ‘node negative’ patients who initially had
LN metastases have a different prognosis when
these metastases completely regress compared to
those who never had metastases. Studies on
oesophageal carcinomas have already demonstrated a
prognostic impact of tumour regression in LN metasta-
ses [12,15–17]. Although generally advocated by the
pathologists’ community [18], and suggested in a recent
expert opinion paper [19], the documentation of regres-
sive changes in LNs and LN metastases in gastric can-
cers is still not routinely performed. Therefore, data on
this issue are available to a much lesser degree. The
only larger study identified in the literature failed to
show convincing evidence for a prognostic value of
tumour regression in LN metastases in an Asian gastric
cancer patient cohort [11,20]. Using a well-
characterised cohort of 480 patients with locally
advanced gastric and gastro-oesophageal junction ade-
nocarcinomas treated with neoadjuvant chemotherapy
followed by gastrectomy from a Western high-volume
surgical centre [7,21], we therefore investigated the
impact of regression in LN metastases.
Material and methods
Patients
The study included 480 histologically proven gastro-
oesophageal(Siewert type II/III) and gastric cancers,
staged cT2-cT4cNany cM0 by endoscopy, endoscopic
ultrasound, and computed tomography of the chest
and abdomen and subsequentially treated in the Surgi-
cal Department of the TUM School of Medicine
between 1991 and 2007 by neoadjuvant chemotherapy
followed by surgery. Siewert type I gastro-oesophageal
cancers, and non-resectable-metastatic disease, were
not included. Neoadjuvant treatment consisted of
either two preoperative cycles of cisplatin or
oxaliplatin/leucovorin/5-FU(PLF/OLF, n = 302), PLF
+ paclitaxel(PLF-T,n = 34), etoposide/adriamycin/cis-
platin (EAP, n = 66 patients) or modified platinum
based regimens (other, n = 78). All surgical procedures
were performed according to the Japanese guidelines
for gastric cancer treatment including standardised
D2-LN dissection. For gastro-oesophageal junction
cancers (Siewert type II and III) the surgical procedure
was extended to the distal oesophagus, either accom-
plished by a transhiatal gastrectomy approach or, if the
oral resection margin determined by intraoperative
frozen section was positive, by an Ivor-Lewis proce-
dure (abdominothoracic oesophagectomy). Patients
were followed up every 6–12 months in the compre-
hensive cancer centre CCCMTUM over the next
5 years by endoscopy and CT scans according to
the institutional protocol. Survival was computed
from the day of surgery. Institutional Review
Board-approval for this study was obtained
according to local guidelines.
TNM staging and pathological parameters
TNM staging was performed according to the eighth
edition of the UICC/AJCC TNM classification
[14]. For additional anatomic subclassification, the
Siewert classification [22] was used. Tumour differen-
tiation (grading) and histological subtyping were per-
formed according to the WHO classification [23]. Data
regarding histopathological tumour regression of the
primary tumour were taken from previous studies
[7,21], using the tumour regression grading (TRG)
system according to Becker [24].
Evaluation of tumour regression in LN metastases
The histological work up of the resection specimens
followed a standardised approach [24]. LNs were
harvested and either completely embedded if the
diameter was <0.5 cm or, otherwise, one
section was taken of the largest diameter. In line
with previous reports on oesophageal and gastric
cancers, hyaline fibrosis, acellular mucin and the
presence of sheets of foamy histiocytes were consid-
ered as characteristic signs of tumour regression
[9–11,20]. In cases where no visible tumour was
detected but regressive changes were present, an
additional three step sections were performed similar
to the approach for the primary tumour [9]. Follow-
ing the recent expert recommendation by Tsekrekos
et al [19] the changes had to be detected in at least
one LN, regardless of the number of affected nodes.
The evaluation of the histological slides was per-
formed prospectively by an experienced gastrointes-
tinal pathologist (KB) at the time of the sign-out of
the surgical resection specimens. In line with other
studies on gastric cancer and similar to the recom-
mendation of Tsekrekos et al [19,20], four catego-
ries of LNs were defined: negative LN without
regressive signs (LN−/Reg−); negative LN with
regressive signs (LN−/Reg+); metastatic LN with
regressive signs (LN+/Reg+) and metastatic LN
without regressive signs (LN+/Reg−) (Figure 1).
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In order to investigate the interobserver agreement
between pathologists, the LNs of an independent set
of 30 cases with gastro-oesophageal adenocarcinomas
treated with neoadjuvant therapy at the Inselspital,
University Hospital Bern, were assessed by two
pathologists (BD, RL). The analyses included 60 slides
with LNs with and without metastases, and the pres-
ence and absence of regressive changes in the LNs of
each slide were scored by the two evaluators indepen-
dently as described above.
Statistical analysis
IBM SPSS Statistics 26 (IBM Corporation, Armonk,
NY, USA) was used for statistical analysis. Compari-
sons between groups and categories were performed
Figure 1. Examples of the LN/Reg categories: (A) LN−/Reg−, no regressive changes in a tumour free lymph node. (B) LN−/Reg+, regres-
sive changes (hyaline fibrosis) without residual tumour. (C) LN+/Reg+, LN with regressive changes but with residual tumour (*marks area
which is magnified in D). (D) Higher magnification of area marked * in (C). (E) acellular mucin in a lymph node as a sign of regression
without residual tumour. (F) LN+/Reg−, Lymph node metastasis without regressive changes.
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using crosstabs, χ2-tests, and Fisher’s exact tests. Sur-
vival analysis encompassed Kaplan–Meier curves and-
log-rank tests for univariate survival analysis and Cox
regression analysis (enter method) for multivariate
analysis. Interobserver agreement for the assessment
of regressive changes was described using kappa
values. P values of <0.05 were considered significant
for all statistical tests.
Results
Patients
The study cohort of 480 patients was described in
detail previously [7,21]. The mean age of patients was
58 years (range: 17–78 years). One hundred and forty
one patients were female and 339 male. The tumours
were located in the gastro-oesophageal junction
(i.e. AEG Type II according to Siewert) in 177 cases.
Three hundred and three cases were gastric cancer
patients, with 83 patients having their tumours in the
cardia/fundus region (i.e. AEG Type III according to
Siewert) and 220 in the corpus and antrum, among
them 21 patients with involvement of the whole stom-
ach (see supplementary material, Table S1).
Pathological data
Seventeen tumours (3.5%) had complete tumour regres-
sion (ypT0), 29 tumours (6%) were ypT1, 42 tumours
(9%) ypT2, 239 tumours (50%) ypT3 and 153 tumours
(32%) were in the ypT4 category. LN metastases were
present in 313 cases (65%), the majority (148 cases) from
the ypN1 category. Complete tumour resection was
achieved in 374 cases (78%). Resectable distant metasta-
ses at the time of surgery were recorded in 72 cases
(15%). Tumours were well to moderately differentiated in
88 cases (18%) and poorly differentiated in 392 cases
(82%). According to the WHO classification, 230 tumours
(48%) were tubular and/or papillary (including solid vari-
ants), 32 tumours (7%) were mucinous, 151 tumours
(32%) poorly cohesive, 41 cases (95) mixed type and
26 cases (5%) other special types. Regression of the pri-
mary tumour was classified according to Becker as
TRG1a (complete regression) in 17 cases (3.5%), TRG1b
(<10% residual tumour) in 85 cases (18%), TRG2
(10–50% residual tumour) in 121 cases (25%) and TRG3
(>50% residual tumour) in 257 cases (53%) (see supple-
mentary material, Table S1).
Regressive changes in LNs
Interobserver agreement for the assessment of regres-
sive changes in LN and LN metastases, respectively
(absence versus presence) was excellent (kappa value
0.846) in the independent case series.
In the study cohort, LN count ranged from 4 to
147 (median = 30). Visible LN metastases were pre-
sent in 313 of 480 cases (65%), ranging from 1 to
116 per case. Regressive changes were observed in a
total of 128 of 480 patients (27%). Using the
categorisation mentioned above, 139 patients had neg-
ative LNs without regression (LN−/Reg−; 29%). The
remaining cases (331; 67%) had either completely
regressed prior LN metastases (LN−/Reg+; n = 28;
6%), visible LN metastases with regressive changes
(LN+/Reg+; n = 100; 21%) or LN metastases without
regression (LN+/Reg−; n = 213; 44%).
Correlation with pathological data
There was a significant correlation between the
LN/Reg categorisation and the following factors
(Table 1): ypT category (p < 0.001), ypN category
(p < 0.001), distant metastases (p = 0.003), re-
section status (p < 0.001) and tumour differentiation
(p < 0.001). There was also a highly significant corre-
lation with TRG (p < 0.001), with for example 17 of
28 (60%) LN−/Reg+ cases in the TRG1b group
(1–10% residual tumour) and 46 of 100 LN+/Reg+
cases (46%) in the TRG2 group (>10–50% residual
tumour). However, some cases showed divergent
response behaviour between primary tumour and LN
metastases: 16 patients showed good response in the
primary and no response in metastatic LNs; and
40 patients demonstrated regressive changes in LN
metastases (two among them complete regression), but
only little or no regression in the primary tumour.
Interestingly, although there was no correlation
between TRG of the primary tumour and the neo-
adjuvant chemotherapy regimen (PLF/OLF/PLF-T ver-
sus EAP and others; p = 0.538), patients who were
treated with PLD/OLF or PLF-T more frequently dem-
onstrated regressive changes in the LNs than patients
treated with other chemotherapy regimens (p = 0.022).
Survival analysis
Survival data were available from 452 patients. Median
follow-up was 29 months (range 1–269 months), com-
prising 17 months (range 1–216 months) for survivors
and 84 months (range 1–269) months for deceased
patients. During the follow-up period 288 patients
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(64%) died, the 5-year survival rate was 40.1%, and the
10 year survival rate was 31.1%.
The following pathological parameters showed a
prognostic impact in univariate analysis: ypT cate-
gory, ypN category, presence of distant metastases,
incomplete tumour resection, tumour grading, histo-
logical subtype according to Lauren and WHO with
a negative impact of poorly cohesive morphology/
diffuse type (p < 0.001 each). Tumour regression
grade of the primary tumour also demonstrated a
highly significant association with prognosis: TRG1
differed from TRG2 (p < 0.001; TRG1a versus
TRG1b; p = 0.2) and TRG2 from TRG3
(p = 0.003), which showed even higher significant
values in survival analysis compared to the original
study with shorter follow-up [21] (overall p < 0.001;
HR = 1.757; 95% CI 1.514–2.041; see supplemen-
tary material, Figure S1).
The LN/Reg-categorisation was also prognostic regard-
ing overall survival, with the best prognosis for LN−/Reg−
and the worst prognosis for LN+/Reg− (overall p < 0.001;
HR = 1.496; 95% CI 1.350–1.658). There was no signifi-
cant difference between LN−/Reg− and LN−/Reg + cases
(p = 0.3). However, LN−/Reg+ cases had a better outcome
than LN+/Reg+ (p = 0.054) and the latter had a better prog-
nosis than LN+/Reg− (p = 0.01; Figure 2).
The LN/Reg categorisation was also an independent
prognostic factor in a multivariate model (HR = 1.23;
95% CI 1.1–1.38; p < 0.001; Table 2), encompassing
ypT category, distant metastases, resection status, tumour
differentiation and WHO subtype, respectively. Exclud-
ing patients with incomplete tumour resection and/or dis-
tant metastases from the survival analysis, leaving
n = 338 patients (n = 316 for survival analysis) the results
were almost identical (overall p < 0.001; HR = 1.534;
95% CI 1.353–1.738). Similar to the complete cohort
Table 1. Lymph node status (LN)/regressive changes (Reg) and pathological parameters.
LN status/regressive changes Total Significance
LN−/Reg− LN−/Reg+ LN+/Reg+ LN+/Reg−
ypT category ypT0 11 3 2 1 17 p < 0.001
ypT1 16 6 3 4 29
ypT2 23 3 6 10 42
ypT3 63 15 57 104 239
ypT4 26 1 32 94 153
ypN category ypN0 139 28 0 0 167 p < 0.001
ypN1 0 0 59 89 148
ypN2 0 0 23 77 100
ypN3 0 0 18 47 65
Distant metastases Absent 131 24 79 174 408 p = 0.003
Present 8 4 21 39 72
Resection status R0 126 24 78 146 374 p < 0.001
R1 13 4 22 67 106
TRG (Becker) 1a 11 3 2 1 17 p < 0.001
1b 39 17 14 15 85
2 37 6 46 32 121
3 52 2 38 165 257
Differentiation (G) 1–2 38 9 18 23 88 p < 0.001
3 11 19 82 190 392
WHO subtype Tub/pap/tubpap/sol 66 19 50 95 230 p = 0.050
Mucinous 4 1 9 18 32
Poorly coh. 54 3 23 71 151
Mixed 9 3 13 16 41
Other 6 2 5 13 26
Localisation GE-junction 52 14 44 67 177 p = 0.066
Stomach 87 14 56 146 303
CTX PLF/OLF/PLF-T 95 22 81 138 336 p = 0.022
Other 44 6 19 75 144
Total 139 28 100 213 480
CTX, chemotherapy; G, grading; GE, gastro-oesophageal; pap, papillary; poorly coh, poorly cohesive; sol, solid; TRG, tumour regression grade; tub, tubular; tubpap,
tubulopapillary.
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Figure 2. Survival analysis. (A) LN/Reg categories, (B) ypN category.
Table 2. Multivariate analysis including LN status/regressive
changes (LN/Reg).
HR
95% CI for HR
P valueLower Upper
ypT category 1.310 1.093 1.570 0.003
LN/Reg category 1.230 1.099 1.378 <0.001
Tumour regression grade 1.266 1.055 1.520 0.011
Differentiation (grade) 1.037 0.792 1.359 0.791
WHO subtype 1.041 0.975 1.111 0.227
Distant metastases 1.361 1.008 1.838 0.044
Resection status 2.028 1.525 2.698 <0.001
Table 3. Multivariate analysis including ypN category.
HR
95.0% CI for HR
SignificanceLower Upper
ypT category 1.228 1.024 1.473 0.027
ypN category 1.456 1.272 1.666 <0.001
Tumour regression grade 1.259 1.052 1.506 0.012
Differentiation (grade) 0.976 0.742 1.283 0.859
WHO subtype 1.040 0.975 1.110 0.231
Distant metastases 1.298 0.960 1.754 0.090
Resection status 1.981 1.489 2.635 <0.0001
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there was no significant difference between LN−/Reg−
and LN−/Reg+ cases (p = 0.206). LN−/Reg+ cases had a
slightly but not significant better outcome than LN+/Reg
+ (p = 0.133) but LN+/Reg− categories were associated
with a better survival than LN+/Reg− (p = 0.049). In
multivariate analysis, the LN/Reg categorisation was an
Figure 3. Survival analysis: subgroup analysis. (A) Subgroup analysis for LN/Reg categories in gastro-oesophageal junction tumours.
(B) Subgroup analysis for LN/Reg categories in gastric cancers. (C) Subgroup analysis for Reg categories for ypN1 patients.
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independent prognostic factor (HR = 1.405; 95% CI
1.175–1.680; p < 0.001; see supplementary material,
Figure S2 and Table S2) also for these patients.
The HR and the significance level of the survival
analyses regarding the LN/Reg categorisation were,
however, of a comparable value to the ypN category
according to UICC/AJCC TNM classification, which
showed very clear prognostic discrimination of four
different groups (ypN0–ypN3; HR = 1.46; 95% CI
1.27–1.67; p < 0.001; Figure 2 and Table 3). Since
these two systems show major overlaps between the
categories, we did not perform a multivariate analysis
including both LN/Reg and ypN categories.
Subgroup analysis: tumour location
Subgroup analysis according to the tumour location
(gastro-oesophageal junction/AEG II versus gastric
cancer) revealed a similar prognostic impact of the
LN/Reg categorisation for both tumour types
(p < 0.001 each; Figure 3).
Subgroup analysis: ypN categories
The most striking prognostic difference between the
subcategories of the LN/Reg categorisation was
observed in the ypN1 category (p = 0.030, Figure 3).
For cases with ypN2 and higher there was no prognos-
tic difference between the subgroups (p = 0.081).
Discussion
We investigated the impact of regressive changes in
LNs of gastric carcinomas and adenocarcinomas of the
gastro-oesophageal junction after neoadjuvant chemo-
therapy. Regressive changes in LNs were observed in
around one quarter of the cases. A small proportion of
patients demonstrated completely regressed former LN
metastases, while mostly there were still visible meta-
static infiltrates detectable despite regression. Most of
the cases showed concordant response behaviour of
the primary tumour and LN metastases. The presence
of regressive changes in LN metastases was associated
with a better survival compared to the absence of
regression in LN metastases. Moreover, the patients
with completely regressed prior LN metastases had an
almost significant better outcome compared to patients
with visible LN metastases with or without regression.
A particular LN classification combining the presence
or absence of tumour and regression showed indepen-
dent prognostic value in a range comparable to the
ypN category.
Our results contradict the findings of a previous
study on gastric cancer by Zhu et al [20], who did not
observe a significant impact of regressive changes in
LN metastases although the authors used the same
categorisation of regressive changes. Differences
between this study and ours include a different ethnic
background (China), a higher number of patients in
our study and fewer cases with regressive changes in
total although, in both studies, neoadjuvant platinum-
based chemotherapy was applied. Martin-Romanoet al
[25] analysed tumour regression of the primary tumour
and the LN metastases in a study that compared two
different neoadjuvant therapy regimens. In line with
our data they demonstrated that patients with complete
regression in initially metastatic LNs had a better prog-
nosis compared with those with residual metastases in
their LNs. Similar to our study, there was no prognos-
tic difference between patients with completely nega-
tive LNs and those with complete regression of a
putatively former metastasis. The study of Martin-
Romanoet al, however, lacks the comparison between
positive LNs with and without regression, which
showed the most striking difference in our analysis.
Data from oesophageal carcinomas that have been
reported by several other groups also support the prog-
nostic value of regressive changes in LNs [12,15–-
–17,26]. These studies also indicate that the TNM ypN
category may not sufficiently reflect the prognostic
impact of LN metastases after neoadjuvant radio-
chemotherapy. Moreover, in line with our observations,
intra-observer agreement for the histopathological deter-
mination of regressive changes was very good
[15]. Other entities in which the prognostic relevance of
regression in LN metastases had a prognostic impact
were breast [27] and rectal cancer [28].
We considered the presence of nodular hyaline
fibrosis, sheets of foamy histiocytes and acellular
mucin in LNs as signs of tumour regression. This has
also been proposed by others [11,20,25], who could
demonstrate that these findings are more frequently
seen in treated tumours or metastases, compared to
cases with primary resection. Our approach to deter-
mine the presence or absence of regression without
further grading is in line with a recently proposed
grading system for LN metastases of gastric cancers
[19] and has been applied in a different study from
China [20]. In addition, and in contrast to TRG in pri-
mary carcinomas, where it usually is possible to esti-
mate the area of the previous tumour (the so-called
tumour bed) by macroscopy and histology, determina-
tion of the size of the initial LN metastases before
treatment has to be considered less objectively. As we
could also demonstrate excellent interobserver
270 D Reim et al
© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society
of Great Britain and Ireland & John Wiley & Sons, Ltd.
J Pathol Clin Res 2020; 6: 263–272
agreement for the determination of regressive changes,
we think that this dichotomising approach is clear and
reliable.
The limitations of this study are as follows. First,
we did not specifically record the number of LNs with
regressive changes. We could, however, demonstrate
that the highest impact of regressive changes was
detectable in the group of ypN1 categories which
encompasses only 1–2 viable LN metastases. More-
over, regarding more detailed reporting on regression
of LN metastasis, it should be also taken into account
that elaborated reporting on each LN separately may
also be impractical in daily routine practice. This has
also been discussed in a recent survey about TRG in
gastrointestinal cancers among gastrointestinal pathol-
ogists [18].
Second, this study also included adenocarcinomas
of the gastro-oesophageal junction/AEG type II
which, according to the updated WHO classification,
should now be grouped with oesophageal cancers. In
our single centre cohort, however, the standardised
treatment of these tumours was gastrectomy, and the
chemotherapy regimen was the same for both loca-
tions [29], as opposed to current standards where
adenocarcinomas of the gastro-oesophageal junction/
AEG type II are frequently treated by neoadjuvant
chemoradiation instead of chemotherapy alone. In
addition, the prognostic impact of the LN/Reg
categorisation was similar for true gastric carcinomas
and gastro-oesophageal junction carcinomas, and our
cohorts are, for both entities separately and in total,
at least to our knowledge, the largest series investi-
gating this topic so far. We therefore felt it appropri-
ate to include both tumour types in an overall
evaluation, while also presenting the data for both
types in a separate analysis.
Third, a recent multicentre study showed the supe-
riority of the FLOT protocol over other treatment
regimens [30]. In this report, higher rates of
favourable TRGs were reported in comparison to
our single centre case collection where additional
taxanes were administered in only a small subset of
patients. In our study, however, regressive changes
were observed more frequently in patients who were
treated with PLF/OLF or PLF-T than in patients
treated with other platinum-based chemotherapy reg-
imens. This suggests that intensified preoperative
treatment may also affect regression in LN metasta-
ses. In this context, it seems appropriate to prospec-
tively collect data regarding regression in LNs and
LN metastases in order to determine not only the
prognostic impact but also the influence of modified
treatment concepts.
In summary, our findings strongly support the prog-
nostic impact of regressive changes in LN metastases
of gastric and gastro-oesophageal junction carcinomas.
This warrants the recommendation that the presence of
tumour regression in LN metastases should be rou-
tinely recorded in pathological reports of gastric and
gastro-oesophageal junction cancers.
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